Results 101 to 110 of about 11,256 (207)

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies

Biomedicines
The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) into the management of ovarian cancer has transformed the treatment landscape for patients affected by this malignancy.
Shant Apelian, Antons Martincuks, Michelle Whittum, Maya Yasukawa, Lindsey Nguy, Begum Mathyk, Vaagn Andikyan, Matthew L. Anderson, Thomas Rutherford, Mihaela Cristea, Daphne Stewart, Adrian Kohut   +11 more
doaj   +1 more source

K63RUb expression sensitizes RNF8-/- MEFs to CPT and PARPi.

, 2014
(A-C) Clonogenic survival of RNF8-/- MEFs uninfected or infected with K63RUb or empty vector (EV) after (A) IR, (B) CPT (24 h) or (C) PARPi (continuous). Data are mean ± s.d.
Daniel Durocher (78101), Bradly G. Wouters (193416), Robert G. Bristow (492990), Roland K. Chiu (113478), Twan van den Beucken (297954), Chantal H. M. A. Ramaekers (529187)   +5 more
core   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science
ABSTRACT Malignant serous effusion (MSE), including malignant pleural effusion (MPE) and malignant ascites (MA), is a common and severe complication in advanced malignancies, associated with poor prognosis and high recurrence rates.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
openaire   +2 more sources

On the Road to PARPi-Platin [PDF]

JNCI: Journal of the National Cancer Institute, 2014
openaire   +2 more sources

FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer

EMBO Molecular Medicine
Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfully targeted in
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova-Todorova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya   +18 more
doaj   +1 more source

Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches

Translational Oncology
While poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have improved the prognosis of ovarian high-grade serous carcinoma (HGSC) tumors that are homologous recombination (HR) deficient (HRD), new therapeutic strategies are needed for tumors that ...
Erika Nakatsuka, Lijun Tan, Brianna Cunneen, Caroline Foster, Yu Leo Lei, Karen McLean   +5 more
doaj   +1 more source

Genetic landscape of homologous recombination repair and practical outcomes of PARPi therapy in ovarian cancer management

Background: Genetic studies of ovarian cancer (OC) have historically focused on BRCA1/2 mutations, lacking other studies of homologous recombination repair (HRR).
Mengyu Chen, Yang Zhao, Liping Han, Qinghe Zhao, Ningyao Tong, Shan Jiang, Luojie Qiu, Ruixia Guo, Kunmei Wang, Lei Chang, Siyu Li, Ningjing Lei, Fengling Wu   +12 more
core   +1 more source

BETting on combination to overcome PARPi resistance

Oncotarget, 2017
Zhang, Youyou, Dang, Chi V., Zhang, Lin
openaire   +2 more sources

Nuclear deformability increases PARPi sensitivity in BRCA1-deficient cells by increasing microtubule-dependent DNA break mobility

Microtubules and nuclear transmembrane SUN1/2 proteins promote the mobility of DNA Double Strand Breaks (DSBs) induced by ionizing radiation and the misrepair of one-ended DSBs induced in BRCA1-deficient cells by Poly(ADP-ribose) polymerase inhibitors ...
Dello Stritto, Angela, Faustini, Elena, Lottersberger, Francisca, Doksani, Ylli, Panza, Andrea   +4 more
core   +1 more source

1209P A new, whole-genome-based PARPi profiler (_ALICE) demonstrates unprecedented efficiency in patient selection for PARPi therapy [PDF]

Annals of Oncology, 2020
P. Zawadzki, A. Piotrowska, M. Wojtaszewska, P. Sztromwasser   +3 more
openaire   +1 more source